Fractyl Health
Fractyl Health's revenue fell 100.0% to $0 million in fiscal 2025. Free cash flow was −$91 million. The diluted share count rose 74.1%.
Net margin is net income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Fractyl Health does
Fractyl Health is developing treatments for obesity and type 2 diabetes that aim at what it sees as their root causes, rather than managing them with drugs taken for life. It is clinical-stage: none of its products is approved for sale in the United States, and it has earned revenue only in Germany, where it began a limited pilot launch of Revita in 2023.
Its lead product, the Revita system, is a procedure done through an endoscope that uses heat to resurface the lining of the duodenum, the first part of the small intestine. Fractyl is testing whether it helps people keep weight off after they stop taking GLP-1 weight loss drugs, which many patients quit. The U.S. Food and Drug Administration has given Revita Breakthrough Device status for that use, and Fractyl planned to ask the agency to approve it in late 2026. Its second program, Rejuva, is a gene therapy delivered to the pancreas with a single procedure, meant to make the body produce GLP-1 on its own; it is at an early stage. If Revita is approved, Fractyl would earn money from selling it, and doctors would need insurers to pay for the procedure.
The company is based in Burlington, Massachusetts, where it also assembles Revita. It had 100 full-time employees in March 2026, most of them in research and development.
Its biggest risks, as it describes them
- Ongoing losses and a need for much more money to keep operating as a going concern.
- Its studies may fail, be delayed or reveal serious side effects.
- Revita may not win approval, and doctors may not use it unless insurers pay for the procedure.
- Its loan agreement has terms that limit its flexibility.
- Doing nearly all its research, manufacturing and storage at a single site.
Income statement
Fractyl Health lost money in fiscal 2025: a net loss of $141 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY23 | FY24 | FY25 |
|---|---|---|---|
| Cash and short-term investments | 33 | 68 | 82 |
| Debt incl. finance leases | 55 | 30 | 31 |
| Net debt (negative means net cash) | 22 | −37 | −51 |
| Net debt to EBITDA | — | — | — |
| Debt to equity | — | 1.1x | 3.2x |
| Interest coverage | −66.7x | −29.9x | −22.5x |
| Current ratio | 3.2x | 3.6x | 4.8x |
| Quick ratio | 3.2x | 3.6x | 4.8x |
Cash flow
Projections
Project Fractyl Health's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What Fractyl Health says to expect
- Second quarter 2027: quarterly operating cash spending
As cost reductions take effect and REMAIN-1 Pivotal Cohort expenditures decline, the Company expects quarterly operating cash spending to be reduced by approximately 50%, to approximately $8 million, by the end of Q2 2027.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 5 insiders bought $187,149 of Fractyl Health shares on the open market, and none sold any.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 14, 2026 | William BradleyDirector | Bought | 64,516 | $0.62 | $40,000 | Form 4 |
| Jun 12, 2026 | Ajay RoyanDirector | Bought | 23,000 | $0.85 | $19,550 | Form 4 |
| Jun 10, 2026 | William BradleyDirector | Bought | 68,493 | $0.73 | $50,000 | Form 4 |
| Jun 10, 2026 | Ian SheffieldDirector | Bought | 35,000 | $0.73 | $25,550 | Form 4 |
| Jun 10, 2026 | Harith RajagopalanChief Executive Officer, Director | Bought | 25,000 | $0.73 | $18,250 | Form 4 |
| Jun 8, 2026 | Weber Lara SmithChief Financial Officer | Bought | 20,000 | $0.69 | $13,800 | Form 4 |
| Dec 4, 2025 | Harith RajagopalanChief Executive Officer, Director | Bought | 10,416 | $1.92 | $19,999 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY24 | FY25 |
|---|---|---|
| Piotroski F-score | — | 3 of 8 |
| Rule of 40 | −72,373.0% | — |
| Altman Z'' | −14.81 | −16.47 |
| Accruals ratio | −3.4% | −44.1% |
The nine F-score tests
| Test | FY24 | FY25 |
|---|---|---|
| Net income is positive | Fail | Fail |
| Cash from operations is positive | Fail | Fail |
| Return on assets rose | — | Fail |
| Cash from operations exceeds net income | Pass | Pass |
| Debt fell relative to assets | — | Pass |
| Current ratio rose | Pass | Pass |
| Share count didn't rise | Fail | Fail |
| Gross margin rose | Pass | — |
| Revenue rose relative to assets | — | Fail |
| F-score | — | 3 of 8 |
Compare
Put Fractyl Health side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Fractyl Health | FY25 | −100.0% | — | — | — | — | 3 | |
| Abbott Laboratories | FY25 | 5.7% | 18.2% | 16.7% | 11.2% | 0.4x | 6 | Compare |
| AdaptHealth | FY25 | −0.5% | 2.8% | 6.8% | 2.1% | 3.5x | 4 | Compare |
| Angiodynamics | FY26 | 9.5% | −12.5% | 0.2% | −24.6% | — | 4 | Compare |
| Anika Therapeutics | FY25 | −5.9% | −9.8% | 3.9% | — | — | — | Compare |
3 years of figures
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Income statement | |||
| Revenue | 0 | 0 | 0 |
| Revenue growth | — | −22.5% | −100.0% |
| Gross profit | 0 | 0 | 0 |
| Research and development | 38 | 70 | 74 |
| Operating income | −51 | −94 | −97 |
| Net income | −77 | −69 | −141 |
| Diluted EPS (US$) | −45.29 | −1.62 | −1.86 |
| Diluted shares (millions) | 2 | 44 | 76 |
| Cash flow | |||
| Cash from operations | −43 | −66 | −90 |
| Capital expenditure | 0 | 2 | 1 |
| Free cash flow | −43 | −67 | −91 |
| Dividends paid | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 |
| Stock-based compensation | 4 | 14 | 7 |
| Balance sheet at fiscal year end | |||
| Cash and short-term investments | 33 | 68 | 82 |
| Debt incl. finance leases | 55 | 30 | 31 |
| Total assets | 76 | 108 | 121 |
| Total liabilities | 114 | 80 | 112 |
| Shareholders' equity | −325 | 28 | 10 |
| Margins and ratios | |||
| Gross margin | 35.8% | 46.2% | — |
| Operating margin | −42,363.3% | −100,571.0% | — |
| Net margin | −64,242.5% | −73,864.5% | — |
| Free cash flow margin | −35,985.0% | −72,350.5% | — |
| Rule of 40 (growth + FCF margin) | — | −72,373.0% | — |
| Return on capital | — | — | — |
| Return on equity | — | — | −744.2% |
| Return on assets | — | −74.5% | −122.8% |
| Net debt to EBITDA | — | — | — |